ArticleFrontiers in endocrinology2026
miR-30d-5p promotes beta cell recovery and immunomodulation in type 1 diabetes.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of insulin-producing beta cells, leading to hyperglycemia. A transient partial remission (PR) phase, marked by improved glycemic control and suppressed autoimmunity, often occurs shortly after diagnosis. We hypothesized that miR-30d-5p, which is highly upregulated during the PR phase in children, may contribute to immune regulation and beta cell recovery. Methods: We investigated the role of miR-30d-5p using human pancreatic slices (HPSs), non-obese diabetic (NOD) mice and human peripheral blood samples. HPSs were transfected with miR-30d-5p oligonucleotides to examine post-transcriptional regulation mechanisms. RNA sequencing was conducted in HPSs to identify differentially expressed genes. Functional assays included insulin secretion, and lineage tracing of beta cells. Additionally, non-obese diabetic (NOD) mice were treated with miR-30d-5p to evaluate effects on diabetes onset and incidence. T cell phenotyping and cytokine secretion were assessed in human T cells from patients with T1D. Results: HPS transfection was successfully achieved, providing a model to investigate the effects of the miRNA in insulin-expressing cells. Functional studies suggested that miR-30d-5p contributes to insulin secretion, and lineage tracing was consistent with the emergence of insulin-producing cells. RNA sequencing identified transcriptional changes associated with pathways related to beta cell function and cellular differentiation. In NOD mice, miR-30d-5p treatment was associated with delayed diabetes onset, suggesting potential immunomodulatory and beta cell-protective effects. In human T lymphocytes, miR-30d-5p was associated with increased expression of inhibitory molecules (PD-1, CTLA-4, CD200, TIM-3, LAG-3) and modulated interferon-gamma secretion. Conclusions: Our findings suggest that miR-30d-5p may participate in in immune cell regulation and processes associated with beta cell recovery in T1D. This study highlights the complex interaction between immune and epigenetic mechanisms during the PR phase and supports further investigation of miR-30d-5p as a potential therapeutic target for preserving beta cell function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.